Neurizon Therapeutics Limited has released a press release.
PharmAust Clinical Trials Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Story so far
Earlier from Neurizon Therapeutics
- PharmAust receives $210k prepayment of forecast R&D rebate
- MPL tablets arrive in Melbourne for MND Clinical Trial
- PharmAust Expands Lymphoma Canine Trial to the USA
- PharmAust Receives $708k R&D Tax Incentive Refund
- PAA appoints trial manager & receives $200k from FightMND
Later from Neurizon Therapeutics
- Update on PharmAust Canine Cancer Trials
- First Patient in US Canine Cancer Trials Begins Treatment
- First Patient Dosed in MND Phase 1/2 Trial
- DNDi contract extension for PharmAust subsidiary Epichem
- MND Trial Completes Enrolment of First Patient Cohort
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics